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 Abstract 
Background: Many patients with primary aldosteronism (PA) show a significant decline in kidney 
function after adrenalectomy. Thus, PA patients who undergo surgery are at greater risk of both 
postoperative renal damage and new-onset metabolic events associated with renal insufficiency. The 
aim of this study was to explore postoperative changes in serum lipid levels and to identify risk 
factors associated with postoperative new-onset dyslipidemia in PA patients. 
Methods: The records of 57 Japanese patients who underwent unilateral laparoscopic adrenalectomy 
for PA were retrospectively surveyed. Clinical and biochemical data were evaluated at baseline and 
12 months after surgery. Preoperative and postoperative estimated glomerular filtration (eGFR) and 
serum lipid profile, including triglycerides, high-density lipoprotein (HDL)-cholesterol and low-
density lipoprotein (LDL)-cholesterol levels, were compared. Furthermore, uni- and multivariate 
analyses were performed to determine the predictors for postoperative new-onset dyslipidemia. 
Results: A significant decrease in eGFR and deterioration of serum lipid levels was identified 
postoperatively in most patients. Of the 39 patients without pre-existing dyslipidemia, 18 developed 
new-onset dyslipidemia postoperatively. Multivariate analysis identified preoperative lower eGFR 
and higher body mass index as independent predictors for new-onset dyslipidemia after surgery. On 
univariate analyses, additional factors associated with new- onset dyslipidemia included older age, 
male sex, higher LDL-cholesterol, and higher LDL/HDL ratio.  
 Conclusions: PA patients had a higher risk of postoperative new-onset or progressive dyslipidemia. 
Clinicians should pay attention to not only follow-up of renal impairment but also total management 
of new-onset metabolic events associated with renal insufficiency in PA patients. 
 Introduction 
  Primary aldosteronism (PA) is caused by the autonomous secretion of aldosterone from 
adrenocortical lesions, and it is associated with hypertension due to sodium retention [1–3]. Excessive 
production of aldosterone in patients with PA has been associated with substantial cardiovascular and 
renal damage [3–7]. Moreover, some studies have reported that aldosterone independently contributes 
to the development of the cardiometabolic syndrome, including hyperglycemia and dyslipidemia [4, 
8]. 
Adrenalectomy can lead to a significant decrease in the glomerular filtration rate, as a consequence 
of correcting the glomerular hyperfiltration peculiar to PA [3, 9–14]. Furthermore, it is well known 
that the progression of renal insufficiency eventually causes cardiometabolic events, such as 
dyslipidemia and premature atherosclerosis [15–20]. Thus, PA patients who undergo adrenalectomy 
are at greater risk of both postoperative renal damage and new- onset metabolic events associated with 
renal insufficiency. So far, there have been no reports on postoperative lipid profile changes in PA 
patients. The aim of the present study was to explore postoperative changes in serum lipid levels and 
to identify risk factors associated with new-onset dyslipidemia after adrenalectomy in Japanese PA 
patients. 
 Materials and Methods 
Medical records at Chiba University Hospital were retrospectively searched from August 1998 to 
March 2013. Unilateral PA was diagnosed as described before and the underlying adrenocortical lesion 
was pathologically assessed in all patients after surgery [2, 9, 10]. All patients were cured with 
postoperative plasma aldosterone concentration (PAC) decreased to <12 ng/dL. Fifty-seven Japanese 
patients who underwent laparoscopic adrenalectomy for unilateral PA were analyzed in the present 
study. Patients with incomplete data about serum lipid profiles or follow- up for <12 months were 
excluded from this study. Eighteen patients had a medical history of dyslipidemia before 
adrenalectomy and 39 did not. None of these patients had taken any lipid-lowering drugs or had any 
medical history of primary kidney disease at the time of surgery. 
The development of new-onset dyslipidemia or deterioration of serum lipid levels was assessed at 
12 months after surgery. Dyslipidemia was defined as hypertriglyceridemia (≥150 mg/dL), hypo-high-
density lipoprotein (HDL)-cholesterolemia (<40 mg/dL), and/or hyper-low-density lipoprotein (LDL)-
cholesterolemia (≥140 mg/dL) according to Japan Arteriosclerosis Society definitions [21]. 
The following were collected from medical records: age, sex, body mass index (BMI), duration of 
hypertension, comorbidities, blood pressure (BP), and clinical laboratory data. These laboratory data 
included PAC, suppressed plasma renin activity (PRA), serum levels of potassium, HDL-cholesterol, 
LDL-cholesterol, and triglycerides, the LDL-cholesterol/HDL-cholesterol (LDL/HDL) ratio, and the 
estimated glomerular filtration rate (eGFR). The eGFR was calculated using a new equation that has 
 been developed and validated in a Japanese population [22]. 
The results are reported as medians (range) or as means ± standard deviation, as appropriate. 
Continuous parametric variables were compared using t-tests. Non-parametric variables were 
compared using Mann-Whitney U tests. Categorical variables were compared using χ2 tests or Fisher’s 
exact test. First, baseline characteristics of patients with/without preoperative dyslipidemia were 
assessed and compared. Second, the changes of eGFR and serum lipid levels in patients were compared 
using paired t-tests or Wilcoxon signed rank tests. Third, univariate analyses were performed to 
evaluate the association between new-onset dyslipidemia and preoperative variables. After significant 
candidate variables were selected based on univariate analyses, multivariate logistic regression 
analysis was used to identify clinical predictors associated with new-onset dyslipidemia. Significance 
was defined at the level of p <0.05. All statistical analyses were carried out using IBM SPSS Statistics 
22. 
 Results 
Table 1 shows the baseline characteristics of the patients, 18 of the 57 PA patients had a medical 
history of dyslipidemia preoperatively. The following variables differed significantly in patients 
with/without preoperative dyslipidemia: medical history of diabetes, PAC, and serum lipid levels. 
Table 2 shows the postoperative changes of eGFR and serum lipid levels in patients with/without 
preoperative dyslipidemia. In both groups, eGFR was significantly lower after surgery. Analysis of 
lipid profiles in 18 patients with preoperative dyslipidemia showed significant increases in LDL-
cholesterol (p =0.02) and the LDL/HDL ratio (p <0.01) postoperatively. On the other hand, analysis  
of lipid profiles in 39 patients without preoperative dyslipidemia showed significant increases in   
triglycerides (p <0.01), in addition to LDL-cholesterol levels and the LDL/HDL ratio. Table 3 shows 
postoperative changes of eGFR and serum lipid levels in patients without preoperative dyslipidemia. 
These patients were divided into two groups according to postoperative eGFR (≥60 and <60 
mL/min/1.73 m2). In the postoperative eGFR <60 mL/min/1.73 m2 group, HDL-cholesterol 
significantly decreased (p <0.01) and triglycerides and the LDL/ HDL ratio significantly increased (p 
<0.01).  Meanwhile, in the postoperative eGFR ≥60 mL/min/1.73 m2 group, LDL-cholesterol 
significantly increased (p =0.03), as did triglycerides (p <0.01).  
 Of the 39 patients without preoperative dyslipidemia, 18 developed dyslipidemia postoperatively. 
Preoperative factors associated with new-onset dyslipidemia on uni- and multivariate analyses are 
summarized in Table 4. On univariate analyses, older age, male sex, higher BMI, lower eGFR, higher 
 LDL-cholesterol, and a higher LDL/HDL ratio were significantly associated with new-onset 
dyslipidemia (p <0.05). LDL-cholesterol and the LDL/HDL ratio were excluded from the variables 
incorporated into the multivariate analysis, because the definition of dyslipidemia was established 
using serum lipid levels. Thus, the following variables were incorporated into the multivariate analysis: 
sex, age, BMI, and eGFR. It was found that higher BMI and lower eGFR were independent predictors 
of new-onset dyslipidemia. 
 
 Discussion 
 Many patients with PA show a significant decline in eGFR postoperatively, because the glomerular 
hyperfiltration state resolves, as we have described before [9]. Additionally, the progression of 
postoperative renal insufficiency causes dyslipidemia and premature atherosclerosis [15-20]. 
Therefore, PA patients who undergo adrenalectomy are at greater risk of both postoperative renal 
damage and new-onset metabolic events associated with renal insufficiency. 
Many studies have shown that chronic kidney disease (CKD) is an important cause of secondary 
dyslipidemia. Abnormalities of serum lipoprotein composition are present in nearly all patients with 
mild to severe renal disease, even those with normal serum lipid levels [15-18]. Generally, the serum 
triglyceride concentration starts to increase with a mild decrease of kidney function [23], while the 
serum HDL-cholesterol concentration is consistently decreased in patients with CKD [15-17, 19]. 
However, the serum LDL-cholesterol concentration tends to remain near normal in patients with CKD, 
but the serum levels of LDL-cholesterol may rise in CKD patients with proteinuria [15-17, 19]. 
In the present study, both patients with postoperative eGFR <60 and those with postoperative eGFR 
≥60 mL/min/1.73 m2 showed a significant decrease in eGFR after adrenalectomy. Moreover, patients 
with postoperative eGFR <60 mL/min/1.73 m2 showed a significant increase in triglycerides and a 
significant decrease in HDL-cholesterol, whereas patients with postoperative eGFR ≥60 mL/min/1.73 
m2 showed a significant increase in triglycerides, but they did not show a significant decrease in HDL-
cholesterol (Table3). The present novel findings suggest that postoperative renal damage could cause 
 the increase of triglycerides and the decrease of HDL-cholesterol. Unfortunately, there is no obvious 
explanation for why LDL-cholesterol significantly after surgery, because proteinuria could not be 
assessed in this retrospective study. 
Although HDL-cholesterol did not show a significant decrease in both patients with/without 
preoperative dyslipidemia, there were significant increases of triglycerides and LDL-cholesterol, and 
there was a tendency towards decreased HDL (Table 2). This study is the first to show that serum lipid 
levels were postoperatively aggravated in PA patients.  
The LDL/HDL ratio has been considered to be a clinically useful marker, because dyslipidemia with 
an increased LDL and decreased HDL predisposes to atherogenesis. Hence, an increased LDL/HDL 
ratio is associated with an increased risk of cardiovascular event, baseline LDL/HDL ratios above 2.5 
are associated with an especially increased cardiovascular event risk [24, 25]. Tables 2 and 3 show that 
the LDL/HDL ratio significantly increased and was above 2.5, except in patients with postoperative 
eGFR ≥60 mL/min/1.73 m2. These findings suggest that the abnormality of postoperative serum lipid 
levels might cause progressive atherosclerosis in PA patients. 
In the present study, clinical predictors for new-onset dyslipidemia after adrenalectomy in PA 
patients were identified first (Table 4). Lower eGFR (p <0.02) and higher BMI (p =0.01) were 
significantly associated with postoperative new-onset dyslipidemia. Renal damage and obesity can 
strongly affect progressive dyslipidemia [19]. These simple clinical factors can be used widely, so 
clinicians are able to pay attention to patients at greater risk of dyslipidemia and decide on suitable 
 early interventions for dyslipidemia. 
The present study has some limitations. The retrospective nature of the study might have affected 
the quality of the data. First, missing data such as consecutive serum lipid profiles and proteinuria 
could not be evaluated. Thus, this small cohort study was finally conducted in 57 patients. Second, this 
study with a follow-up of 12 months might have been too short to assess renal failure and dyslipidemia 
in PA patients. Although the present study represents the first report of the effects of surgical 
management of PA on the development of dyslipidemia, further study is needed to corroborate these 
findings and to further clarify these associations. 
In conclusion, PA patients had a higher risk of new-onset or progressive dyslipidemia after 
laparoscopic adrenalectomy. Clinicians should pay attention to not only follow-up of renal 
impairment, but also comprehensive management of new-onset metabolic events associated with 
renal insufficiency in PA patients. 
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 Table 1. Baseline characteristics of patients with primary aldosteronism 
Variable 
With preoperative 
dyslipidemia (N=18) 
Without preoperative 
dyslipidemia (N=39) 
p 
Age, years 54.0 (45.0-72.0) 54.0 (23.0-73.0) 0.26 
Male, n (%) 8 (44.4) 20 (51.3) 0.63 
BMI (kg/m2) 24.4 (±3.4) 22.9 (±3.1) 0.12 
Duration of hypertension, 
years 
7.0 (1.0-27.0) 10.0 (0.0-30.0) 0.49 
Comorbidities    
 Cardiovascular disease, n 
(%) 
1 (5.6) 8 (20.5) 0.15 
 Cerebrovascular disease, n 
(%) 
3 (16.7) 3 (7.7) 0.28 
Diabetes mellitus, n (%) 6 (33.3) 4 (10.3) 0.04 
Systolic BP (mmHg) 147.2 (±24.5) 152.4 (±23.9) 0.46 
Diastolic BP (mmHg) 93.5 (±16.1) 90.6 (±16.8) 0.54 
PAC (ng/dL) 28.8 (±27.3) 40.3(±30.6） 0.02 
PRA (ng/mL/h) 0.1 (0.0-1.0) 0.2 (0.0-4.1) 0.57 
Potassium (mmol/L) 3.0 (±0.5) 3.1 (±0.7) 0.58 
 eGFR (mL/min/1.73 m2) 73.7 (±16.3) 80.3 (±21.6) 0.26 
HDL-cholesterol (mg/dL) 49.8 (±13.5) 63.4 (±18.5) <0.01 
LDL-cholesterol (mg/dL) 134.1 (±21.9) 109.9 (±20.6) <0.01 
Triglycerides (mg/dL) 164.4 (±65.3) 83.0 (±24.2) <0.01 
LDL/HDL ratio 2.8 (±0.7) 1.9 (±0.6) <0.01 
BMI, body mass index; BP, blood pressure; PAC, plasma aldosterone concentration; PRA, plasma 
renin activity; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low 
density lipoprotein. 
  
 Table 2. Postoperative changes of serum lipid levels in patients with primary aldosteronism 
Variable Before surgery After surgery p 
With preoperative dyslipidemia (N=18)   
eGFR (mL/min/1.73 m2) 73.7 (±16.3) 59.8 (±15.4) <0.01 
HDL-cholesterol(mg/dL) 49.8 (±13.5) 45.6 (±13.0) 0.16 
LDL-cholesterol(mg/dL) 134.1 (±21.9) 144.6 (±23.8) 0.02 
Triglycerides (mg/dL) 164.4 (±65.3) 209.0 (±82.3) 0.05 
LDL/HDL ratio 2.8 (±0.7) 3.4 (±1.3) <0.01 
Without preoperative dyslipidemia (N=39)   
eGFR (mL/min/1.73 m2) 80.3 (±21.6) 64.4 (±17.4) <0.01 
HDL-cholesterol(mg/dL) 63.4 (±18.5) 60.4 (±20.5) 0.15 
LDL-cholesterol(mg/dL) 109.9 (±20.6) 119.7 (±26.3) <0.01 
Triglycerides (mg/dL) 83.0 (±24.2) 136.8 (±70.2) <0.01 
LDL/HDL ratio 1.9 (±0.6) 2.3 (±1.0) <0.01 
New-onset dyslipidemia in patients without preoperative dyslipidemia (N=18) 
eGFR (mL/min/1.73 m2) 65.6 (±12.8) 50.6 (±8.3) <0.01 
HDL-cholesterol(mg/dL) 62.5 (±23.1) 57.6 (±25.3) 0.15 
LDL-cholesterol(mg/dL) 115.7 (±15.7) 128.4 (±26.1) <0.01 
Triglycerides (mg/dL) 81.7 (±23.9) 158.3 (±94.2) <0.01 
 LDL/HDL ratio 2.2 (±0.6) 3.0 (±0.9) <0.01 
eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density 
lipoprotein. 
 
 Table 3. Postoperative changes of serum lipid levels in patients without preoperative 
dyslipidemia 
Variables Before surgery After surgery p 
Postoperative eGFR <60 (N=14)   
eGFR (mL/min/1.73 m2) 63.1 (±16.3) 46.8 (±11.0) <0.01 
HDL-cholesterol(mg/dL) 61.4 (±20.8) 52.2 (±25.6) <0.01 
LDL-cholesterol(mg/dL) 119.8 (±11.2) 133.8 (±26.4) 0.06 
Triglycerides (mg/dL) 89.6 (±27.8) 171.9 (±82.6) <0.01 
LDL/HDL ratio 2.1 (±0.6) 3.0 (±1.0) <0.01 
Postoperative eGFR ≥60 (N=25)   
eGFR (mL/min/1.73 m2) 89.9 (±18.0) 74.3 (±11.3) <0.01 
HDL-cholesterol(mg/dL) 64.5 (±17.5) 65.0 (±15.7) 0.69 
LDL-cholesterol(mg/dL) 104.3 (±22.7) 111.9 (±23.3) 0.03 
Triglycerides (mg/dL) 79.4 (±21.7) 117.2 (±54.7) <0.01 
LDL/HDL ratio 1.8 (±0.6) 1.8 (±0.7) 0.26 
eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density 
lipoprotein. 
 
 Table 4. Uni- and multivariate analyses of preoperative variables for new-onset dyslipidemia in 
patients with primary aldosteronism 
Preoperative 
variables 
Univariate Multivariate 
New-onset 
dyslipidemia 
(n=18) 
Non new-onset 
dyslipidemia (n=21) 
p 
Odds ratio 
(95% CI) 
p 
Age (years) 67.1 (±4.6) 59.7 (±1.5) 0.03  - 0.44 
Male, n (%) 13 (72.2) 6 (28.6) <0.01 - 0.32 
BMI (kg/m2) 26.2 (18.9-27.0) 23.2 (19.2-23.8) <0.01 1.11-2.33 0.01 
Duration of 
hypertension 
(years) 
19.5 (1.50-30.0) 10.0 (10.0-17.0) 0.06    
Comorbidities     
 Cardiovascular 
disease, n (%) 
3 (16.7) 5 (23.8) 0.70    
 Cerebrovascular 
disease, n (%) 
1 (5.5) 2 (9.5) 1.00    
 Diabetes 
mellitus, n (%) 
3 (16.7) 1 (4.7) 0.32    
Systolic BP 
(mmHg) 
147.2 (±29.8) 157.7 (±24.6) 0.94    
Diastolic BP 
(mmHg) 
79.8 (±16.0) 76.3 (±13.1) 0.26    
PAC (ng/dL) 31.6 (11.6-48.2) 31.3 (24.0-31.5) 0.28    
PRA (ng/mL/h) 0.2 (±0.1) 0.2 (±0.2) 0.17    
Potassium, 
(mmol/L) 
3.5 (±0.7) 3.0 (±0.4) 0.10    
eGFR 
(mL/min/1.73 m2) 
60.8 (42.6-81.3) 69.4 (69.4-81.1) <0.01 0.86-0.97 <0.01 
HDL-cholesterol 
(mg/dL) 
54.3 (±14.8) 63.0 (±22.9) 0.07    
LDL-cholesterol 
(mg/dL) 
120.5 (±7.7) 101.7 (±22.5) <0.01 - - 
Triglycerides 
(mg/dL) 
89.3 (±27.8) 73.3 (±11.9) 0.17    
LDL/HDL ratio 2.2 (±0.6) 1.6 (±0.5) <0.01 - - 
  
BMI, body mass index; BP, blood pressure; PAC, plasma aldosterone concentration; PRA, plasma 
renin activity; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low 
density lipoprotein; CI, confidence interval. 
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